Ken Belotsky
Partner @ Negev Capital
Vienna, Austria
Ken Belotsky is a seed investor at Negev Capital in Vienna focused on Health Care and Biotechnology. Ken Belotsky is based out of Vienna and is the Founder of Negev Labs. Ken previously worked at Bright Box as a Executive Board Director. Ken Belotsky attended Columbia Business School.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Ken Belotsky invests in
Stages Ken Belotsky invests in
Countries Ken Belotsky invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (40%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Biopharma 1 (20%)
- Nutraceutical 1 (20%)
Stage
- Seed 2 (40%)
- Post-IPO Equity 2 (40%)
Country
- Canada 3 (60%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.7M / Post-IPO Equity / Jun 03, 2024 | ||
| Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.8M / Post-IPO Equity / Jul 19, 2023 | ||
| BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage theimmune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. | $474K / Post-IPO Equity / Dec 07, 2022 | ||
| Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system,Ketamine oral mucosa delivery system. | Seed / Sep 21, 2021 | ||
NanoPsy
|
NanoPsy is a company that develops nanotechnology for theranostic applications to effectively improve psychedelic drug efficacy. Our patented nano technology which, in combination with our targeted delivery and controlled dosing technology methods, will allow for an increase in solubility/absorption of these molecules. Thus a more efficaciousAPI. | $403.3K / Seed / Jun 29, 2021 |
Co-Investors
About Negev Capital
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$21+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, and therapeutic use of psychedelicinterventions for neuropsychiatric disorders; as well as those who have excellent management and science teams, and robust IP. Negev believes that psychedelic medications will be not only disruptive to the practice of psychiatry but hold the potential to reduce enormous amounts of human suffering, and is committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.
Negev Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ken Belotsky
Partner
|
|||
Vadim E. Uzberg
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ken Belotsky invest in?
Ken Belotsky invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Post-IPO Equity stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ken Belotsky?
Public channels for Ken Belotsky include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ken Belotsky last invest?
The most recent investment recorded for Ken Belotsky closed in Jun 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
